This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

Switching from and to ELIQUIS® (apixaban)

Choose ELIQUIS®

When switching to ELIQUIS please ensure you have considered the patient’s various factors that may influence the dosing of ELIQUIS e.g. indication, age, weight, renal function. See SmPC for full information.

Switching to ELIQUIS1

dosing-switching-to-eliquis dosing-switching-to-eliquis

Switching from ELIQUIS

dosing-switching-from-eliquis dosing-switching-from-eliquis

Please refer to the ELIQUIS Summary of Product Characteristics (SmPC) for more information.

We have developed a checklist to support healthcare professionals when prescribing
eliquis for stroke prevention in patients with NVAF switching from warfarin

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1

Footnotes:

  • BD = Twice Daily   DOAC = Direct-acting Oral Anticoagulant   INR = International Normalised Ratio   SmPC = Summary of Product Characteristics   UFH = Unfractionated Heparin

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Steffel J et al. Eur Heart J 2018; 39: 1330–1393.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com